Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR2 | Q969V1 | 8/20 | 0.38 |
| ▸ | DRD2 | P14416 | 3/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | NAE1 | Q13564 | 2/20 | 0.34 |
| ▸ | UBA3 | Q8TBC4 | 2/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13644082 | 0.88 | MCHR2 (0.38) | MCHR2DRD2SLC6A4KCNH2NAE1 | |
| SCHEMBL13640856 | 0.85 | MCHR2 (0.38) | MCHR2DRD2SLC6A4KCNH2NAE1 | |
| SCHEMBL13640716 | 0.83 | MCHR2 (0.53) | MCHR2DRD2SLC6A4KCNH2SIGMAR1 | |
| SCHEMBL13640732 | 0.83 | MCHR2 (0.45) | MCHR2DRD2SLC6A4KCNH2HSD11B1 | |
| SCHEMBL13640826 | 0.81 | CCR5 (0.35) | MCHR2KCNH2CCR5SIGMAR1CYP2D6 | |
| SCHEMBL13641017 | 0.80 | MCHR2 (0.43) | MCHR2DRD2SLC6A4KCNH2NAE1 | |
| SCHEMBL13640789 | 0.80 | MCHR2 (0.43) | MCHR2DRD2SLC6A4KCNH2NAE1 | |
| SCHEMBL13644014 | 0.78 | MCHR2 (0.36) | MCHR2DRD2SLC6A4KCNH2NAE1 | |
| SCHEMBL13640966 | 0.75 | MCHR2 (0.38) | MCHR2DRD2SLC6A4KCNH2NAE1 | |
| SCHEMBL13640854 | 0.75 | KCNH2 (0.36) | MCHR2DRD2SLC6A4KCNH2CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497295-B2 | Spiroindoline modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-30 | — | — | US | disclosed |
| US-20120283243-A1 | Spiroindoline Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283243-A1 | Spiroindoline Modulators of Muscarinic Receptors | CHRM3, CHRM2, CHRM5 | MCHR2 179/4885DRD2 491/4885SLC6A4 827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.